Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection ... hematopoietic stem-cell transplant (HSCT) recipients, and patients receiving ...

Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment ...

Previous studies on regulatory T-cell (Treg) reconstitution after allogeneic hematopoietic SCT (HSCT) have suggested that, within the GVHD process, imbalance between effector T cells and Tregs may ...

A timely medical intervention in the form of a bone marrow transplant, medically known as hematopoietic stem cell ...

WHO declared the start of the COVID-19 pandemic. Although patients with haematological malignancies have greatly benefited ...

Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone ...

FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy ...

Zydus Lifesciences announced that it has launch ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) ...

Theoretically, HSCT offers 2 major advantages in the treatment ... During the first part of this phase, the major problems encountered are infections from endogenous bacteria, the reactivation ...

The company launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will ...